TNF and cancer: IOI-42, as a novel small molecule inhibitor of hPEBP4, has been reported to sensitize tumor cells to TNF-α and TRAIL-mediated apoptosis [20], suggesting that hPEBP4 interference with a specific pharmacologic inhibitor is capable of sensitizing cancer cells when used in combination with other drugs.